Floatz logo

Hydroxychloroquine

Refractory Cancer

N.N. Petrov National Medical Research Center of OncologySmall moleculePhase 2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
73/ 100

Competitive context

44 Active assets in the Refractory Cancer cohort.

Asset / SponsorPhaseRating
Eloxatin
M.D. Anderson Cancer Center
Phase 2B
Tocilizumab
University Health Network, Toronto
Phase 4B
Pembrolizumab
GV20 Therapeutics
Phase 2B
Irinotecan
Children's Oncology Group
Phase 2B
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

Hydroxychloroquine is also rated in:

cutaneous melanomaDormant
B
Indicative ·
61 / 100
View asset →
prostate cancerDormant
B
Indicative ·
60 / 100
View asset →
pancreatic adenocarcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →